ETR:EVT Evotec (EVT) Stock Price, News & Analysis €4.74 +0.03 (+0.64%) As of 05/19/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Evotec Stock (ETR:EVT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Evotec alerts:Sign Up Key Stats Today's Range€4.69▼€4.8850-Day Range€4.12▼€5.6952-Week Range€5.06▼€21.69Volume857,146 shsAverage Volume1.36 million shsMarket Capitalization€879.48 millionP/E RatioN/ADividend Yield2.63%Price TargetN/AConsensus RatingN/A Company Overview Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. Read More Receive EVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVT Stock News HeadlinesEvotec SE Posts Weak Q1 2026 but Doubles Down on ‘Horizon’ Transformation and Mid-Term Growth TargetsMay 6, 2026 | tipranks.comEvotec Strengthens Supervisory Board and Strikes Governance Pact With MAK CapitalApril 30, 2026 | tipranks.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 20 at 1:00 AM | Brownstone Research (Ad)Evotec SE: Evotec Announces New Nomination to Board of DirectorsApril 29, 2026 | finanznachrichten.deIs It Time To Reassess Evotec (XTRA:EVT) After The Recent 24.5% Share Price JumpApril 18, 2026 | finance.yahoo.comEvotec (XTRA:EVT) Valuation Check After Recent Share Price ReboundApril 17, 2026 | finance.yahoo.comEvotec SE: Evotec Appoints Dr. Ingrid Müller as Chief Operating OfficerApril 15, 2026 | finanznachrichten.deEvotec Names New Supervisory Board Chair and Expects $100 Million Windfall From Tubulis DealApril 7, 2026 | tipranks.comSee More Headlines EVT Stock Analysis - Frequently Asked Questions How have EVT shares performed this year? Evotec's stock was trading at €5.45 on January 1st, 2026. Since then, EVT shares have decreased by 13.0% and is now trading at €4.74. What other stocks do shareholders of Evotec own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evotec investors own include Bank of America (BAC), Evotec (EVTCY), Intel (INTC), NVIDIA (NVDA), AbbVie (ABBV), Applied Materials (AMAT) and KLA (KLAC). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryFinancial Services Current SymbolETR:EVT CIKN/A Webwww.evotec.com Phone+49-40-560810FaxN/AEmployees5,061Year FoundedN/AProfitability EPS (Trailing Twelve Months)(€0.92) Trailing P/E RatioN/A Forward P/E Ratio55.23 P/E Growth0.98Net Income-€179.29 million Net Margins-26.02% Pretax MarginN/A Return on Equity-24.55% Return on Assets0.97% Debt Debt-to-Equity Ratio55.38 Current Ratio1.68 Quick Ratio2.97 Sales & Book Value Annual Sales€749.92 million Price / Sales1.17 Cash Flow€1.37 per share Price / Cash Flow3.45 Book Value€3.94 per share Price / Book1.20Miscellaneous Outstanding Shares185,544,981Free FloatN/AMarket Cap€879.48 million OptionableNot Optionable Beta1.24 Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (ETR:EVT) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredHow to Access Elon’s “Monster” Interest RateMost Americans earn just 0.4% on their savings - that's $40 a year on $10,000. A new banking alternative is of...InvestorPlace | SponsoredThe “tell” for the end of the AI boomThe real question about AI stocks in 2026 isn't whether to own them - it's knowing exactly when to get in and ...Stansberry Research | SponsoredAfter June 1, don't say I didn't warn youMacroeconomic Strategist Dr. Mark Skousen of The Oxford Club says one date should be at the top of every inves...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
